The vaccine, which comes in a pre-filled syringe for active immunization against coronavirus disease, is intended for people aged 12 and older.
Keystone / Ti-Press / Samuel Golay
The Swiss Agency for Therapeutic Products (Swissmedic) has approved an updated COVID-19 vaccine from US-based pharmaceutical company Moderna.
+Get the most important news from Switzerland in your inbox
The vaccine, which comes in a pre-filled syringe for active immunization against coronavirus disease, is intended for people aged 12 and older.
Swissmedic confirmed Moderna’s press release on Monday. According to the company, the approval of the COVID-19 vaccine Spikevax LP.8.1 is based on manufacturing data as well as existing clinical, non-clinical, and real-world data demonstrating the efficacy and safety of Moderna’s mRNA COVID-19 vaccines.
Accordingly, manufacturing data (CMC – Chemistry, Manufacturing and Control) and preclinical data, but no new clinical data, were submitted for the approval of this new variant.
Translated from German by DeepL/jdp
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch.
